References
- Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn Microbiol Infect Dis 1999; 33(2): 101–12
- Somani J, Bhullar VB, Workowski KA, et al. Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000; 181(4): 1421–7
- Balfour JA, Lamb HM. Moxifloxacin: a review of its' clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000; 59(1): 115–39
- Chodosh S, DeAbate CA, Haverstock D, et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94(1): 18–27
- Patel T, Pearl J, Williams J, et al. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respir Med 2000; 94(2): 97–105
- DeAbate CA, Mclvor RA, McElvaine P, et al. Gatifloxacin vs cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. J Respir Dis 1999; 20(Suppl 11): S23–9
- Fogarty C, Dowell ME, Ellison WT, et al. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999; 20(Suppl 11): S60-9
- Linden PK, Pasculle AW, McDevitt D, et al. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: comparison with a control cohort. J Antimicrob Chemother 1997; 39(Suppl A): 145–51
- Mandler HD, Blumberg EA, Fuchs AE, et al. Arthralgias and myalgias associated with quinupristin/dalfopristin (Synercid) treatment of infections caused by vancomycin-resistant Enterococcus faecium (VREF). (Abstr) Clin Infect Dis 1998; 27: 1035
- Clemett D, Markham A. Linezolid. Drugs 2000; 59(4): 815–27
- Chien JW, Kucia ML, Salata RA. Use of linezolid, an oxazolidinone, in the treatment of multidrug-resistant gram-positive bacterial infections. Clin Infect Dis 2000; 30(1): 146–51
- Vergis EN, Indorf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch Intern Med 2000; 160(9): 1294–300
- Ailani RK, Agastya G, Ailani RK, et al. Doxycycline is a cost-effective therapy for hospitalized patients with community-acquired pneumonia. Arch Intern Med 1999; 159(3): 266–70
- Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341(4): 233–9
- Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160 (10): 1399–408